GSK137647A, a diarylsulfonamide analog, is a novel, potent and selective agonists of the free fatty acid receptor 4 (FFA4/GPR120) with pEC50 of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, respectively. GSK137647A prefers to target GPR120 above a panel of 61 other targets, which includes additional FFARs. The G protein-coupled receptor family contains the free fatty acid receptor 4 (FFA4/GPR120), a putative 7TM (transmembrane) receptor that is involved in the secretion of glucagon-like peptide-1 (GLP-1) in response to long-chain fatty acid stimulation. The intestinal endocrine cell line STC-1 and the intestine both exhibit high expression levels of FFA4.
Physicochemical Properties
| Molecular Formula | C₁₆H₁₉NO₃S | |
| Molecular Weight | 305.39 | |
| Exact Mass | 305.109 | |
| Elemental Analysis | C, 62.93; H, 6.27; N, 4.59; O, 15.72; S, 10.50 | |
| CAS # | 349085-82-1 | |
| Related CAS # |
|
|
| PubChem CID | 743974 | |
| Appearance | White to off-white solid powder | |
| LogP | 4.575 | |
| Hydrogen Bond Donor Count | 1 | |
| Hydrogen Bond Acceptor Count | 4 | |
| Rotatable Bond Count | 4 | |
| Heavy Atom Count | 21 | |
| Complexity | 411 | |
| Defined Atom Stereocenter Count | 0 | |
| SMILES | S(C1C([H])=C([H])C(=C([H])C=1[H])OC([H])([H])[H])(N([H])C1C(C([H])([H])[H])=C([H])C(C([H])([H])[H])=C([H])C=1C([H])([H])[H])(=O)=O |
|
| InChi Key | FQUAFMNPXPXOJE-UHFFFAOYSA-N | |
| InChi Code | InChI=1S/C16H19NO3S/c1-11-9-12(2)16(13(3)10-11)17-21(18,19)15-7-5-14(20-4)6-8-15/h5-10,17H,1-4H3 | |
| Chemical Name | 4-methoxy-N-(2,4,6-trimethylphenyl)benzenesulfonamide | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | GPR120 | |
| ln Vitro |
|
|
| ln Vivo |
GSK137647A (GSK 137647) (1 mg/kg; i.p.; twice daily, for 7 days) reduces colitis in C57BL/6 mice given TNBS and DSS[1]. GSK137647A (GSK 137647) (1 mg/kg; i.p.; twice daily, for 7 days; C57BL/6 mice) increases intestinal permeability in vivo[1]. |
|
| Cell Assay |
Cell Line: Caco-2 cells Concentration: 30 µM Incubation Time: 12 hours Result: Downregulated FFAR1, FFAR2, and FFAR4 as compared to control. |
|
| Animal Protocol |
Male C57BL/6 mice 1 mg/kg Intraperitoneal injection; twice daily, for 7 days |
|
| References |
[1]. Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice. Nutrients. 2021 Aug 6;13(8):2716. [2]. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett. 2014 Jul 15;24(14):3100-3. |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2745 mL | 16.3725 mL | 32.7450 mL | |
| 5 mM | 0.6549 mL | 3.2745 mL | 6.5490 mL | |
| 10 mM | 0.3275 mL | 1.6373 mL | 3.2745 mL |